[96a5a0]: / output / chiaCancer / identified / NCT00050349_identified.json

Download this file

672 lines (672 with data), 29.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
{
"info": {
"nct_id": "NCT00050349",
"official_title": "EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors",
"inclusion_criteria": "* Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy\n* The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)\n* Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry\n* Must have a life expectancy of greater than three (3) months\n* Karnofsky Performance Status > 60\n* Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Patients with symptomatic CNS metastases or leptomeningeal involvement\n* Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression.\n* Patients with bone metastases as the only site(s) of measurable disease\n* Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease)\n* Patients who have been previously treated with radioactive directed therapies\n* Patients who have been previously treated with epothilone\n* Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1\n* Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports\n* Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ\n* Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae\n* Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits\n* HIV+ patients\n* Pregnant or lactating females.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy",
"criterions": [
{
"exact_snippets": [
"biopsy-proven metastatic carcinoid tumors"
],
"criterion": "metastatic carcinoid tumors",
"requirement_type": "confirmation",
"expected_value": true
},
{
"exact_snippets": [
"biopsy-proven",
"other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas)"
],
"criterion": "neuroendocrine tumors",
"requirement_type": "confirmation",
"expected_value": true
},
{
"exact_snippets": [
"at least one measurable lesion"
],
"criterion": "measurable lesion",
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1
}
]
}
},
{
"exact_snippets": [
"other than bone"
],
"criterion": "lesion location",
"requirement_type": "exclusion",
"expected_value": "bone"
},
{
"exact_snippets": [
"not been previously irradiated"
],
"criterion": "lesion irradiation history",
"requirement_type": "history",
"expected_value": false
},
{
"exact_snippets": [
"if previously irradiated has demonstrated progression since the radiation therapy"
],
"criterion": "lesion progression post-irradiation",
"requirement_type": "progression",
"expected_value": true
}
]
},
{
"line": "* The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)",
"criterions": [
{
"exact_snippets": [
"no major impairment of renal or hepatic function"
],
"criterion": "renal function",
"requirement_type": "impairment",
"expected_value": false
},
{
"exact_snippets": [
"no major impairment of renal or hepatic function"
],
"criterion": "hepatic function",
"requirement_type": "impairment",
"expected_value": false
},
{
"exact_snippets": [
"total bilirubin <1.5 X ULN"
],
"criterion": "total bilirubin",
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 1.5
}
},
{
"exact_snippets": [
"AST, ALT<2.5X ULN"
],
"criterion": "AST",
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2.5
}
},
{
"exact_snippets": [
"AST, ALT<2.5X ULN"
],
"criterion": "ALT",
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2.5
}
},
{
"exact_snippets": [
"<5 X ULN if liver metastases are present"
],
"criterion": "AST",
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 5
}
},
{
"exact_snippets": [
"<5 X ULN if liver metastases are present"
],
"criterion": "ALT",
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 5
}
},
{
"exact_snippets": [
"if liver metastases are present"
],
"criterion": "liver metastases",
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"line": "* Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry",
"criterions": [
{
"exact_snippets": [
"Patients on Sandostatin Lar",
"must be on a stable dose for 30 days prior to study entry"
],
"criterion": "Sandostatin Lar",
"requirement_type": "dose stability",
"expected_value": "stable for 30 days"
},
{
"exact_snippets": [
"short acting somatostatin analogues",
"must be judged to be on a clinically stable dose by the investigator prior to study entry"
],
"criterion": "short acting somatostatin analogues",
"requirement_type": "dose stability",
"expected_value": "clinically stable"
}
]
},
{
"line": "* Must have a life expectancy of greater than three (3) months",
"criterions": [
{
"exact_snippets": [
"life expectancy of greater than three (3) months"
],
"criterion": "life expectancy",
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 3
}
}
]
},
{
"line": "* Karnofsky Performance Status > 60",
"criterions": [
{
"exact_snippets": [
"Karnofsky Performance Status > 60"
],
"criterion": "Karnofsky Performance Status",
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 60
}
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": [
"Healthy volunteers allowed"
],
"criterion": "healthy volunteers",
"requirement_type": "participation",
"expected_value": true
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": [
"minimum age of 18 Years"
],
"criterion": "age",
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18
}
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients with symptomatic CNS metastases or leptomeningeal involvement",
"criterions": [
{
"exact_snippets": [
"symptomatic CNS metastases"
],
"criterion": "CNS metastases",
"requirement_type": "symptomatic",
"expected_value": true
},
{
"exact_snippets": [
"leptomeningeal involvement"
],
"criterion": "leptomeningeal involvement",
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"line": "* Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression.",
"criterions": [
{
"exact_snippets": [
"known brain metastases"
],
"criterion": "brain metastases",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"metastases have been treated"
],
"criterion": "brain metastases",
"requirement_type": "treatment status",
"expected_value": true
},
{
"exact_snippets": [
"metastases have been",
"stable for at least six months"
],
"criterion": "brain metastases",
"requirement_type": "stability duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 6
}
]
}
},
{
"exact_snippets": [
"history of brain metastases"
],
"criterion": "brain metastases",
"requirement_type": "history",
"expected_value": true
},
{
"exact_snippets": [
"head CT with contrast"
],
"criterion": "head CT with contrast",
"requirement_type": "requirement",
"expected_value": true
},
{
"exact_snippets": [
"document either response or progression"
],
"criterion": "brain metastases",
"requirement_type": "documentation of response or progression",
"expected_value": true
}
]
},
{
"line": "* Patients with bone metastases as the only site(s) of measurable disease",
"criterions": [
{
"exact_snippets": [
"bone metastases"
],
"criterion": "bone metastases",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"measurable disease"
],
"criterion": "measurable disease",
"requirement_type": "site",
"expected_value": "bone"
}
]
},
{
"line": "* Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease)",
"criterions": [
{
"exact_snippets": [
"hepatic artery chemoembolization within the last 6 months"
],
"criterion": "hepatic artery chemoembolization",
"requirement_type": "recency",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 6
}
]
}
},
{
"exact_snippets": [
"hepatic artery chemoembolization",
"one month if there are other sites of measurable disease"
],
"criterion": "hepatic artery chemoembolization",
"requirement_type": "recency",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 1
}
]
}
}
]
},
{
"line": "* Patients who have been previously treated with radioactive directed therapies",
"criterions": [
{
"exact_snippets": [
"previously treated with radioactive directed therapies"
],
"criterion": "radioactive directed therapies",
"requirement_type": "prior treatment",
"expected_value": true
}
]
},
{
"line": "* Patients who have been previously treated with epothilone",
"criterions": [
{
"exact_snippets": [
"Patients who have been previously treated with epothilone"
],
"criterion": "epothilone treatment",
"requirement_type": "history",
"expected_value": true
}
]
},
{
"line": "* Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1",
"criterions": [
{
"exact_snippets": [
"Patients with any peripheral neuropathy"
],
"criterion": "peripheral neuropathy",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"unresolved diarrhea greater than Grade 1"
],
"criterion": "diarrhea",
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 1
}
}
]
},
{
"line": "* Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports",
"criterions": [
{
"exact_snippets": [
"severe cardiac insufficiency"
],
"criterion": "cardiac insufficiency",
"requirement_type": "severity",
"expected_value": "severe"
},
{
"exact_snippets": [
"taking Coumadin or other warfarin-containing agents"
],
"criterion": "warfarin-containing agents",
"requirement_type": "usage",
"expected_value": true
},
{
"exact_snippets": [
"low dose warfarin (1 mg or less)"
],
"criterion": "warfarin dose",
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 1
}
]
}
}
]
},
{
"line": "* Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ",
"criterions": [
{
"exact_snippets": [
"Patients taking any experimental therapies"
],
"criterion": "experimental therapies",
"requirement_type": "usage",
"expected_value": true
},
{
"exact_snippets": [
"history of another malignancy within 5 years prior to study entry"
],
"criterion": "another malignancy",
"requirement_type": "history",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 5
}
]
}
},
{
"exact_snippets": [
"except curatively treated non-melanoma skin cancer"
],
"criterion": "non-melanoma skin cancer",
"requirement_type": "treatment status",
"expected_value": "curatively treated"
},
{
"exact_snippets": [
"except curatively treated",
"prostate cancer"
],
"criterion": "prostate cancer",
"requirement_type": "treatment status",
"expected_value": "curatively treated"
},
{
"exact_snippets": [
"except curatively treated",
"cervical cancer in situ"
],
"criterion": "cervical cancer in situ",
"requirement_type": "treatment status",
"expected_value": "curatively treated"
}
]
},
{
"line": "* Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae",
"criterions": [
{
"exact_snippets": [
"active or suspected acute or chronic uncontrolled infection"
],
"criterion": "infection",
"requirement_type": "control",
"expected_value": false
},
{
"exact_snippets": [
"abcesses"
],
"criterion": "abcesses",
"requirement_type": "presence",
"expected_value": false
},
{
"exact_snippets": [
"fistulae"
],
"criterion": "fistulae",
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"line": "* Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits",
"criterions": [
{
"exact_snippets": [
"medical or psychiatric illness"
],
"criterion": "medical or psychiatric illness",
"requirement_type": "presence",
"expected_value": false
},
{
"exact_snippets": [
"history of noncompliance to medical regimens"
],
"criterion": "noncompliance to medical regimens",
"requirement_type": "history",
"expected_value": false
},
{
"exact_snippets": [
"inability or unwillingness to return for all scheduled visits"
],
"criterion": "ability to return for scheduled visits",
"requirement_type": "willingness",
"expected_value": true
}
]
},
{
"line": "* HIV+ patients",
"criterions": [
{
"exact_snippets": [
"HIV+ patients"
],
"criterion": "HIV",
"requirement_type": "status",
"expected_value": "positive"
}
]
},
{
"line": "* Pregnant or lactating females.",
"criterions": [
{
"exact_snippets": [
"Pregnant"
],
"criterion": "pregnancy",
"requirement_type": "status",
"expected_value": false
},
{
"exact_snippets": [
"lactating"
],
"criterion": "lactation",
"requirement_type": "status",
"expected_value": false
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "* Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.)",
"criterions": [
{
"exact_snippets": [
"Female patients"
],
"criterion": "gender",
"requirement_type": "specificity",
"expected_value": "female"
},
{
"exact_snippets": [
"negative serum pregnancy test"
],
"criterion": "pregnancy test",
"requirement_type": "result",
"expected_value": "negative"
},
{
"exact_snippets": [
"at screening"
],
"criterion": "pregnancy test",
"requirement_type": "timing",
"expected_value": "at screening"
},
{
"exact_snippets": [
"Not applicable to patients with bilateral oophorectomy"
],
"criterion": "bilateral oophorectomy",
"requirement_type": "procedure history",
"expected_value": true
},
{
"exact_snippets": [
"Not applicable to patients with",
"hysterectomy"
],
"criterion": "hysterectomy",
"requirement_type": "procedure history",
"expected_value": true
},
{
"exact_snippets": [
"Not applicable to patients who are postmenopausal"
],
"criterion": "menopausal status",
"requirement_type": "status",
"expected_value": "postmenopausal"
}
]
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}